Jeroncellevain, a company specializing in the production of prescription drugs, announced on June 10 that a paper proposing the term "Osteoimmunologic Integration" has been published in the International Journal of Molecular Sciences (IF 4.9), a journal by the global publishing group MDPI (Multidisciplinary Digital Publishing Institute).
This research was co-authored by Kim Deokgyu, CEO of Jeroncellevain; Yoon Jongil, Vice President of the PDRN Immunoregenerative Dentistry Society and Director of Yeon Dental Clinic; Kim Jaehong, President of the PDRN Immunoregenerative Dentistry Society and Director of Seoul Top Dental Clinic; Yoon Suin, graduate of the University of Pittsburgh; and Lee Deokwon, Director of The One Oral Surgery Clinic.
The paper, titled "Mediation of Osseointegration, Osteoimmunology, and Osteoimmunologic Integration by Tregs and Macrophages: A Narrative Review," interprets the process of osseointegration following implant procedures from an immunological perspective, based on the bone formation regulatory activities of regulatory T cells (Tregs) and macrophages.
Significantly, the paper is the first in the world to propose the term "Osteoimmunologic Integration," advancing the traditional concept of osseointegration to a new level.
Yoon Jongil, the first author of the paper, Vice President of the PDRN Immunoregenerative Dentistry Society and Director of Yeon Dental Clinic, stated, "Implant osseointegration has been one of the most significant topics in dentistry for the past 40 years, but scientific understanding of the phenomenon has been lacking. However, with recent remarkable advances in immunology, the osteoimmunological mechanisms underlying osseointegration are now being revealed."
He added, "An osteoimmunological understanding will provide clinical clues for the success and maintenance of implants, helping to raise the level of clinical outcomes. In particular, PDRN, a DNA fragment (f DNA), is expected to serve as an osteoimmunological modulator for the success and maintenance of implants."
PDRN is known as an economical and practical drug among existing prescription medicines, as it is expected to regulate inflammation and aid tissue regeneration without side effects, attracting significant interest from dentists. In this paper, PDRN is introduced as a promising candidate drug for immune regulation, inflammation reduction, and bone regeneration in implant osseointegration, peri-implantitis, and periodontitis, as it promotes the secretion of vascular endothelial growth factor (VEGF) and anti-inflammatory cytokine (IL-10), demonstrates excellent efficacy in tissue regeneration and bone formation, and is effective in inhibiting bone resorption induced by RANKL (receptor activator of nuclear factor kappa-B ligand), a protein involved in bone resorption.
Kim Deokgyu, CEO of Jeroncellevain, commented, "The publication of this paper signifies that our research and development capabilities have been recognized internationally. Moving forward, we will continue to grow as a company that leads high-value-added pharmaceuticals and regenerative medicine technologies, based on academic contributions as clinicians."
He continued, "We plan to further strengthen our technological leadership in the global market by expanding the potential applications in various biomedical fields, including the development of therapeutics based on tissue regeneration and immune modulation."
The full text of the paper is available on the official website of the International Journal of Molecular Sciences (IJMS) as of June 5, 2025.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
